HYDERGINE
LOE ApproachingNDASUBLINGUALTABLET
Approved
Nov 1953
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYDERGINE is a sublingual tablet small molecule approved in 1953 by Novartis with an unknown mechanism of action and indication profile. The product's exact therapeutic use cannot be determined from available data, but its 70+ year history suggests a legacy indication in a mature market segment.
LOE Approaching
Product approaching loss of exclusivity with low competitive pressure (30%), suggesting minimal commercial investment and likely team consolidation in coming years.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on HYDERGINE represents a defensive or transitional career move in a legacy product with minimal job linked opportunities and declining market dynamics. This role suits professionals seeking stability in a niche therapeutic area or those preparing for generic transition management.
Brand ManagerProduct Manager
Worked on HYDERGINE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.